1. 1. Alexopoulos G. S., Meyers B. S., Young R. C., Kalayam B., Kakuma T., Gabrielle M., Sirey J. A., Hull J. (2000). Executive dysfunction and long-term outcomes of geriatric depression. Arch. Gen. Psychiatry 57, 285–29010.1001/archpsyc.57.3.285 - DOI - PubMed
2. 1. Allen N. B., Badcock P. B. T. (2003). The social risk hypothesis of depressed mood: evolutionary, psychosocial, and neurobiological perspectives. Psychol. Bull. 129, 887–91310.1037/0033-2909.129.6.887 - DOI - PubMed
3. 1. Allen N. B., Badcock P. B. T. (2006). Darwinian models of depression: a review of evolutionary accounts of mood and mood disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 30, 815–82610.1016/j.pnpbp.2006.01.007 - DOI - PubMed
4. 1. Amat J., Aleksejev R. M., Paul E., Watkins L. R., Maier S. F. (2010). Behavioral control over shock blocks behavioral and neurochemical effects of later social defeat. Neuroscience 165, 1031–103810.1016/j.neuroscience.2009.11.005 - DOI - PMC - PubMed
5. 1. Amat J., Baratta M. V., Paul E., Bland S. T., Watkins L. R., Maier S. F. (2005). Medial prefrontal cortex determines how stressor controllability affects behavior and dorsal raphe nucleus. Nat. Neurosci. 8, 365–37110.1038/nn1399 - DOI - PubMed
6. 1. Amat J., Paul E., Zarza C., Watkins L. R., Maier S. F. (2006). Previous experience with behavioral control over stress blocks the behavioral and dorsal raphe nucleus activating effects of later uncontrollable stress: role of the ventral medial prefrontal cortex. J. Neurosci. 26, 13264–1327210.1523/JNEUROSCI.3630-06.2006 - DOI - PMC - PubMed
7. 1. American Psychiatric Association (APA). (2000). (DSM-IV-TR) Diagnostic and Statistical Manual of Mental Disorders, 4th Edn. Washington, DC: American Psychiatric Press, Inc
8. 1. Amsterdam J. D., Bodkin J. A. (2006). Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial. J. Clin. Psychopharmacol. 26, 579–58610.1097/01.jcp.0000239794.37073.70 - DOI - PubMed
9. 1. Andrews P. W., Aggen S. H., Miller G. F., Radi C., Dencoff J. E., Neale M. C. (2007). The functional design of depression's influence on attention: a preliminary test of alternative control-process mechanisms. Evol. Psychol. 5, 584–604
10. 1. Andrews P. W., Thomson J. A., Jr. (2009). The bright side of being blue: depression as an adaptation for analyzing complex problems. Psychol. Rev. 116, 620–65410.1037/a0016242 - DOI - PMC - PubMed
11. 1. Anisman H., Matheson K. (2005). Stress, depression, and anhedonia: caveats concerning animal models. Neurosci. Biobehav. Rev. 29, 525–54610.1016/j.neubiorev.2005.03.007 - DOI - PubMed
12. 1. Anton S. F., Robinson D. S., Roberts D. L., Kensler T. T., English P. A., Archibald D. G. (1994). Long-term treatment of depression with nefazodone. Psychopharmacol. Bull. 30, 165–169 - PubMed
13. 1. Badcock P. B. T., Allen N. B. (2003). Adaptive social reasoning in depressed mood and depressive vulnerability. Cogn. Emot. 17, 647–67010.1080/02699930302299 - DOI - PubMed
14. 1. Baldessarini R. J., Ghaemi S. N., Viguera A. C. (2002). Tolerance in antidepressant treatment. Psychother. Psychosom. 71, 177–17910.1159/000063641 - DOI - PubMed
15. 1. Bano S., Gitay M., Ara I., Badawy A. (2010). Acute effects of serotonergic antidepressants on tryptophan metabolism and corticosterone levels in rats. Pak. J. Pharm. Sci. 23, 266–272 - PubMed
16. 1. Baratta M. V., Zarza C. M., Gomez D. M., Campeau S., Watkins L. R., Maier S. F. (2009). Selective activation of dorsal raphe nucleus-projecting neurons in the ventral medial prefrontal cortex by controllable stress. Eur. J. Neurosci. 30, 1111–111610.1111/j.1460-9568.2009.06867.x - DOI - PMC - PubMed
17. 1. Beck A. T., Beamesderfer A. (1974). “Assessment of depression: the depression inventory,” in Modern Problems in Pharmacopsychiatry, ed. Pichot P. (Basel: Karger; ), 151–169 - PubMed
18. 1. Bel N., Artigas F. (1995). In vivo evidence for the reversible action of the monoamine oxidase inhibitor brofaromine on 5-hydroxytryptamine release in rat brain. Naunyn Schmiedebergs Arch. Pharmacol. 351, 475–48210.1007/BF00171038 - DOI - PubMed
19. 1. Berton O., Nestler E. J. (2006). New approaches to antidepressant drug discovery: beyond monoamines. Nat. Rev. Neurosci. 7, 137–15110.1038/nrn1846 - DOI - PubMed
20. 1. Best J., Nijhout H. F., Reed M. (2010). Serotonin synthesis, release and reuptake in terminals: a mathematical model. Theor. Biol. Med. Model. 10.1186/1742-4682-7-34 - DOI - PMC - PubMed
21. 1. Bongiovanni R., Newbould E., Jaskiw G. E. (2008). Tyrosine depletion lowers dopamine synthesis and desipramine-induced prefrontal cortex catecholamine levels. Brain Res. 1190, 39–4810.1016/j.brainres.2007.10.079 - DOI - PubMed
22. 1. Brandts C. H., Ndjave M., Graninger W., Kremsner P. G. (1997). Effect of paracetamol on parasite clearance time in Plasmodium falciparum malaria. Lancet 350, 704–70910.1016/S0140-6736(97)02255-1 - DOI - PubMed
23. 1. Bremner J. D., Smith W. T. (1996). Org 3770 vs amitriptyline in the continuation treatment of depression: a placebo controlled trial. Eur. J. Psychiatry 10, 5–15
24. 1. Bursztajn H. J., Brodsky A. (1998). Ethical and legal dimensions of benzodiazepine prescription: a commentary. Psychiatr. Ann. 28, 121–128 - PubMed
25. 1. Bymaster F. P., Zhang W., Carter P. A., Shaw J., Chernet E., Phebus L., Wong D. T., Perry K. W. (2002). Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl.) 160, 353–36110.1007/s00213-001-0986-x - DOI - PubMed
26. 1. Byrne S. E., Rothschild A. J. (1998). Loss of antidepressant efficacy during maintenance therapy: possible mechanisms and treatments. J. Clin. Psychiatry 59, 279–28810.4088/JCP.v59n0602 - DOI - PubMed
27. 1. Campbell I., Marshall E. (1974). Effects of chronic regimes of phenelzine, tranylcypromine and imipramine on rat brain noradrenaline and 5-hydroxytryptamine. J. Pharmacol. 5, 14–15
28. 1. Cheung A., Kusumakar V., Kutcher S., Dubo E., Garland J., Weiss M., Kiss A., Levitt A. (2008). Maintenance study for adolescent depression. J. Child Adolesc. Psychopharmacol. 18, 389–39410.1089/cap.2008.0001 - DOI - PubMed
29. 1. Chouinard G. (2004). Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J. Clin. Psychiatry 65, 7–12 - PubMed
30. 1. Claghorn J. L., Feighner J. P. (1993). A double-blind comparison of paroxetine with imipramine in the long-term treatment of depression. J. Clin. Psychopharmacol. 13, S23–S2710.1097/00004714-199312002-00004 - DOI - PubMed
31. 1. Cook B. L., Helms P. M., Smith R. E., Tsai M. (1986). Unipolar depression in the elderly: reoccurrence on discontinuation on tricyclic antidepressants. J. Affect. Disord. 10, 91–9410.1016/0165-0327(86)90031-5 - DOI - PubMed
32. 1. Coppen A., Ghose K., Montgomery S., Rao V. A. R., Bailey J., Jorgensen A. (1978). Continuation therapy with amitriptyline in depression. Br. J. Psychiatry 133, 28–3310.1192/bjp.133.3.206 - DOI - PubMed
33. 1. Coryell W., Endicott J., Winokur G., Akiskal H., Solomon D., Leon A., Mueller T., Shea T. (1995). Characteristics and significance of untreated major depressive disorder. Am. J. Psychiatry 152, 1124–1129 - PubMed
34. 1. Cryan J. F., O'Leary O. F., Jin S. H., Friedland J. C., Ouyang M., Hirsch B. R., Page M. E., Dalvi A., Thomas S. A., Lucki I. (2004). Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors. Proc. Natl. Acad. Sci. U.S.A. 101, 8186–819110.1073/pnas.0401080101 - DOI - PMC - PubMed
35. 1. Dantzer R. (2001). Cytokine-induced sickness behavior: where do we stand? Brain Behav. Immun. 15, 7–2410.1006/brbi.2000.0613 - DOI - PubMed
36. 1. Davidson J., Raft D. (1984). Use of phenelzine in continuation therapy. Neuropsychobiology 11, 191–19410.1159/000118076 - DOI - PubMed
37. 1. Dawson L. A., Li P. (2003). Effects of 5-HT6 receptor blockade on the neurochemical outcome of antidepressant treatment in the frontal cortex of the rat. J. Neural Transm. 110, 577–59010.1007/s00702-003-0812-1 - DOI - PubMed
38. 1. Detke M. J., Wiltse C. G., Mallinckrodt C. H., McNamara R. K., Demitrack M. A., Bitter I. (2004). Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur. Neuropsychopharmacol. 14, 457–47010.1016/j.euroneuro.2004.01.002 - DOI - PubMed
39. 1. Dobson K. S., Hollon S. D., Dimidjian S., Schmaling K. B., Kohlenberg R. J., Gallop R. J., Rizvi S. L., Gollan J. K., Dunner D. L., Jacobson N. S. (2008). Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the prevention of relapse and recurrence in major depression. J. Consult. Clin. Psychol. 76, 468–47710.1037/0022-006X.76.3.468 - DOI - PMC - PubMed
40. 1. Doogan D. P., Caillard V. (1992). Sertraline in the prevention of depression. Br. J. Psychiatry 160, 217–22210.1192/bjp.160.2.217 - DOI - PubMed
41. 1. Drevets W. C. (1998). Functional neuroimaging studies of depression: the anatomy of melancholia. Annu. Rev. Med. 49, 341.10.1146/annurev.med.49.1.341 - DOI - PubMed
42. 1. Duman R. S. (2004). Depression: a case of neuronal life and death? Biol. Psychiatry 56, 140–14510.1016/j.biopsych.2004.02.033 - DOI - PubMed
43. 1. Duman R. S., Monteggia L. M. (2006). A neurotrophic model for stress-related mood disorders. Biol. Psychiatry 59, 1116–112710.1016/j.biopsych.2006.02.013 - DOI - PubMed
44. 1. Dziedzicka-Wasylewska M., Faron-Gorecka A., Kusmider M., Drozdowska E., Rogoz Z., Siwanowicz J., Caron M. G., Bönisch H. (2006). Effect of antidepressant drugs in mice lacking the norepinephrine transporter. Neuropsychopharmacology 31, 2424–243210.1038/sj.npp.1301064 - DOI - PubMed
45. 1. Emslie G. J., Kennard B. D., Mayes T. L., Nightingale-Teresi J., Carmody T., Hughes C. W., Rush A. J., Tao R., Rintelmann J. W. (2008). Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. Am. J. Psychiatry 165, 459–46710.1176/appi.ajp.2007.07091453 - DOI - PMC - PubMed
46. 1. Entsuah A. R., Rudolph R. L., Hackett D., Miska S. (1996). Efficacy of venlafaxine and placebo during long-term treatment of depression: a pooled analysis of relapse rates. Int. Clin. Psychopharmacol. 11, 137–14510.1097/00004850-199611020-00008 - DOI - PubMed
47. 1. Eric L. (1991). A prospective, double-blind, comparative, multicentre study of paroxetine and placebo in preventing recurrent major depressive episodes. Biol. Psychiatry 29, 254S–255S
48. 1. Fava G. A., Offidani E. (2011). The mechanisms of tolerance in antidepressant action. Prog. Neuropsychopharmacol. Biol. Psychiatry. [Epub ahead of print].10.1016/j.pnpbp.2010.07.026 - DOI - PubMed
49. 1. Fava M. (2006). Prospective studies of adverse events related to antidepressant discontinuation. J. Clin. Psychiatry 67, 14–2110.4088/JCP.v67n1113 - DOI - PubMed
50. 1. Finberg J. P. M., Pacak K., Kopin I. J., Goldstein D. S. (1993). Chronic inhibition of monoamine oxidase type A increases noradrenaline release in rat frontal cortex. Naunyn Schmiedebergs Arch. Pharmacol. 347, 500–50510.1007/BF00166742 - DOI - PubMed
51. 1. Fournier J. C., DeRubeis R. J., Hollon S. D., Dimidjian S., Amsterdam J. D., Shelton R. C., Fawcett J. (2010). Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 303, 47–5310.1001/jama.2009.1943 - DOI - PMC - PubMed
52. 1. Fuller R. W., Perry K. W., Molloy B. B. (1974). Effect of an uptake inhibitor on serotonin metabolism in rat brain: studies with 3-para-trifluoromethylphenoxy)-n-methyl-3-phenylpropylamine (Lilly 110140). Life Sci. 15, 1161–117110.1016/S0024-3205(74)80012-3 - DOI - PubMed
53. 1. Geddes J. R., Carney S. M., Davies C., Furukawa T. A., Kupfer D. J., Frank E., Goodwin G. M. (2003). Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 361, 653–66110.1016/S0140-6736(03)12599-8 - DOI - PubMed
54. 1. Georgotas A., Mccue R. E., Cooper T. B. (1989). A placebo-controlled comparison of nortriptyline and phenelzine in maintenance therapy of elderly depressed-patients. Arch. Gen. Psychiatry 46, 783–786 - PubMed
55. 1. Gilaberte I., Montejo A. L., de la Gandara J., Perez-Sola V., Bernardo M., Massana J., Martin-Santos R., Santiso A., Noguera R., Casais L., Perez-Camo V., Arias M., Judge R. Fluoxetine Long-Term Study Group. (2001). Fluoxetine in the prevention of depressive recurrences: a double-blind study. J. Clin. Psychopharmacol. 21, 417–42410.1097/00004714-200108000-00009 - DOI - PubMed
56. 1. Gilbert P. (2006). Evolution and depression: issues and implications. Psychol. Med. 36, 287–29710.1017/S0033291705006112 - DOI - PubMed
57. 1. Gilbert P., Allan S. (1998). The role of defeat and entrapment (arrested flight) in depression: an exploration of an evolutionary view. Psychol. Med. 28, 585–59810.1017/S0033291798006710 - DOI - PubMed
58. 1. Gilbert P., Gilbert J., Irons C. (2004). Life events, entrapments and arrested anger in depression. J. Affect. Disord. 79, 149–16010.1016/S0165-0327(02)00405-6 - DOI - PubMed
59. 1. Glue P., Donovan M. R., Kolluri S., Emir B. (2010). Meta-analysis of relapse prevention antidepressant trials in depressive disorders. Aust. N. Z. J. Psychiatry 44, 697–70510.3109/00048671003705441 - DOI - PubMed
60. 1. Goldberg D., Privett M., Ustun B., Simon G., Linden M. (1998). The effects of detection and treatment on the outcome of major depression in primary care: a naturalistic study in 15 cities. Br. J. Gen. Pract. 48, 1840–1844 - PMC - PubMed
61. 1. Gorwood P., Weiller E., Lemming O., Katona C. (2007). Escitalopram prevents relapse in older patients with major depressive disorder. Am. J. Geriatr. Psychiatry 15, 581–59310.1097/01.JGP.0000240823.94522.4c - DOI - PubMed
62. 1. Guy W. (1976). ECDEU Assessment Manual for Psychopharmacology-Revised (DHEW publication no. ADM 76-338). Rockville, MD: US Department of Health, Education, and Welfare
63. 1. Haddad P. (1997). Newer antidepressants and the discontinuation syndrome. J. Clin. Psychiatry 58, 17–22 - PubMed
64. 1. Hagen E. H. (1999). The functions of postpartum depression. Evol. Hum. Behav. 20, 325–35910.1016/S1090-5138(99)00016-1 - DOI
65. 1. Hagen E. H. (2002). Depression as bargaining – The case postpartum. Evol. Hum. Behav. 23, 323–33610.1016/S1090-5138(01)00102-7 - DOI
66. 1. Hagen E. H. (2003). “The bargaining model of depression,” in The Genetic and Cultural Evolution of Cooperation, ed. Hammerstein P. (Cambridge, MA: MIT Press; ), 95–123
67. 1. Hamilton M. (1960). A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23, 56–6210.1136/jnnp.23.3.239 - DOI - PMC - PubMed
68. 1. Harrison W., Rabkin J., Stewart J. W., McGrath P. J., Tricamo E., Quitkin F. (1986). Phenelzine for chronic depression: a study of continuation treatment. J. Clin. Psychiatry 47, 346–349 - PubMed
69. 1. Hasday J. D., Fairchild K. D., Shanholtz C. (2000). The role of fever in the infected host. Microbes Infect. 2, 1891–190410.1016/S1286-4579(00)01337-X - DOI - PubMed
70. 1. Heisler L. K., Chu H. M., Brennan T. J., Danao J. A., Bajwa P., Parsons L. H., Tecott L. H. (1998). Elevated anxiety and antidepressant-like responses in serotonin 5-HT1A receptor mutant mice. Proc. Natl. Acad. Sci. U.S.A. 95, 15049–1505410.1073/pnas.95.25.15049 - DOI - PMC - PubMed
71. 1. Hochochka P. W., Somero G. N. (2002). Biochemical Adaptation: Mechanism and Process in Physiological Evolution. New York, NY: Oxford University Press
72. 1. Hochstrasser B., Isaksen P. M., Koponen H., Lauritzen L., Mahnert F. A., Rouillon F., Wade A. G., Andersen M., Pedersen S. F., Swart J. C., Nil R. (2001). Prophylactic effect of citalopram in unipolar, recurrent depression – Placebo-controlled study of maintenance therapy. Br. J. Psychiatry 178, 304–31010.1192/bjp.178.4.304 - DOI - PubMed
73. 1. Hollon S. D., Stewart M. O., Strunk D. (2006). Enduring effects for cognitive behavior therapy in the treatment of depression and anxiety. Annu. Rev. Psychol. 57, 285–31510.1146/annurev.psych.57.102904.190044 - DOI - PubMed
74. 1. Horwitz A. V., Wakefield J. C. (2007). The Loss of Sadness: How Psychiatry Transformed Normal Sorrow into Depressive Disorder. New York, NY: Oxford University Press - PubMed
75. 1. Hyman S. E., Nestler E. J. (1996). Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am. J. Psychiatry 153, 151–162 - PubMed
76. 1. Jordan S., Kramer G. L., Zukas P. K., Moeller M., Petty F. (1994). In vivo biogenic amine efflux in medial prefrontal cortex with imipramine, fluoxetine, and fluvoxamine. Synapse 18, 294–29710.1002/syn.890180404 - DOI - PubMed
77. 1. Kalueff A. V., Wheaton M., Murphy D. L. (2007). What's wrong with my mouse model? Advances and strategies in animal modeling of anxiety and depression. Behav. Brain Res. 179, 1–1810.1016/j.bbr.2007.01.023 - DOI - PubMed
78. 1. Kamijima K., Burt T., Cohen G., Arano I., Hamasaki T. (2006). A placebo-controlled, randomized withdrawal study of sertraline for major depressive disorder in Japan. Int. Clin. Psychopharmacol. 21, 1–910.1097/01.yic.0000194382.18825.78 - DOI - PubMed
79. 1. Kaymaz N., van Os J., Loonen A. J. M., Nolen W. A. (2008). Evidence that patients with single versus recurrent depressive episodes are differentially sensitive to treatment discontinuation: a meta-analysis of placebo-controlled randomized trials. J. Clin. Psychiatry 69, 1423–143610.4088/JCP.v69n0910 - DOI - PubMed
80. 1. Keller M. B., Kocsis J. H., Thase M. E., Gelenberg A. J., Rush A. J., Koran L., Schatzberg A., Russell J., Hirschfeld R., Klein D., McCullough J. P., Fawcett J. A., Kornstein S., LaVange L., Harrison W. (1998). Maintenance phase efficacy of sertraline for chronic depression - A randomized controlled trial. JAMA 280, 1665–167210.1001/jama.280.19.1665 - DOI - PubMed
81. 1. Keller M. C., Neale M. C., Kendler K. S. (2007). Association of different adverse life events with distinct patterns of depressive symptoms. Am. J. Psychiatry 164, 1521–152910.1176/appi.ajp.2007.06091564 - DOI - PubMed
82. 1. Keller M. C., Nesse R. M. (2004). Subtypes of low mood provide evidence for its adaptive significance. J. Affect. Disord. 78, S77–S78
83. 1. Keller M. C., Nesse R. M. (2005). Is low mood an adaptation? Evidence for subtypes with symptoms that match precipitants. J. Affect. Disord. 86, 27–3510.1016/j.jad.2004.12.005 - DOI - PubMed
84. 1. Keller M. C., Nesse R. M. (2006). The evolutionary significance of depressive symptoms: different adverse situations lead to different depressive symptom patterns. J. Pers. Soc. Psychol. 91, 316–33010.1037/0022-3514.91.2.316 - DOI - PubMed
85. 1. Kendler K. S., Thornton L. M., Gardner C. O. (2000). Stressful life events and previous episodes in the etiology of major depression in women: an evaluation of the “kindling” hypothesis. Am. J. Psychiatry 157, 1243–125110.1176/appi.ajp.157.8.1243 - DOI - PubMed
86. 1. Kesner R. P. (2000). Subregional analysis of mnemonic functions of the prefrontal cortex in the rat. Psychobiology 28, 219–228
87. 1. Kessler R. C., Berglund P., Demler O., Jin R., Walters E. E. (2005). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch. Gen. Psychiatry 62, 593–60210.1001/archpsyc.62.6.617 - DOI - PubMed
88. 1. Kessler R. C., Merikangas K. R., Wang P. S. (2007). Prevalence, comorbidity, and service utilization for mood disorders in the United States at the beginning of the twenty-first century. Annu. Rev. Clin. Psychol. 3, 137–15810.1146/annurev.clinpsy.3.022806.091444 - DOI - PubMed
89. 1. Kihara T., Ikeda M. (1995). Effects of duloxetine, a new serotonin and norepinephrine uptake inhibitor, on extracellular monoamine levels in rat frontal cortex. J. Pharmacol. Exp. Ther. 272, 177–183 - PubMed
90. 1. Kirsch I., Deacon B. J., Huedo-Medina T. B., Scoboria A., Moore T. J., Johnson B. T. (2008). Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 5, 260–26810.1371/journal.pmed.0050045 - DOI - PMC - PubMed
91. 1. Kitaichi Y., Inoue T., Nakagawa S., Boku S., Izumi T., Koyama T. (2010). Combined treatment with MAO-A inhibitor and MAO-B inhibitor increases extracellular noradrenaline levels more than MAO-A inhibitor alone through increases in beta-phenylethylamine. Eur. J. Pharmacol. 637, 77–8210.1016/j.ejphar.2010.04.014 - DOI - PubMed
92. 1. Klerman G. L., Dimascio A., Weissman M., Prusoff B., Paykel E. S. (1974). Treatment of depression by drugs psychotherapy. Am. J. Psychiatry 131, 186–191 - PubMed
93. 1. Klysner R., Bent-Hansen J., Hansen H. L., Lunde M., Pleidrup E., Poulsen D. L., Andersen M., Petersen H. E. (2002). Efficacy of citalopram in the prevention of recurrent depression in elderly patients: placebo-controlled study of maintenance therapy. Br. J. Psychiatry 181, 29–3510.1192/bjp.181.1.29 - DOI - PubMed
94. 1. Koch S., Hemrick-Luecke S. K., Thompson L. K., Evans D. C., Threlkeld P. G., Nelson D. L., Perry K. W., Bymaster F. P. (2003). Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology 45, 935–94410.1016/S0028-3908(03)00268-5 - DOI - PubMed
95. 1. Kocsis J. H., Friedman R. A., Markowitz J. C., Leon A. C., Miller N. L., Gniwesch L., Parides M. (1996). Maintenance therapy for chronic depression – A controlled clinical trial of desipramine. Arch. Gen. Psychiatry 53, 769–774 - PubMed
96. 1. Kocsis J. H., Thase M. E., Trivedi M. H., Shelton R. C., Kornstein S. G., Nemeroff C. B., Friedman E. S., Gelenberg A. J., Dunner D. L., Hirschfeld R. M., Rothschild A. J., Ferguson J. M., Schatzberg A. F., Zajecka J. M., Pedersen R. D., Yan B., Ahmed S., Musgnung J., Ninan P. T., Keller M. B. (2007). Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT study. J. Clin. Psychiatry 68, 1014–102310.4088/JCP.v68n0706 - DOI - PubMed
97. 1. Krishnan V., Nestler E. J. (2008). The molecular neurobiology of depression. Nature 455, 894–90210.1038/nature07455 - DOI - PMC - PubMed
98. 1. Kruijshaar M. E., Barendregt J., Vos T., de Graaf R., Spijker J., Andrews G. (2005). Lifetime prevalence estimates of major depression: an indirect estimation method and a quantification of recall bias. Eur. J. Epidemiol. 20, 103–11110.1007/s10654-004-1009-0 - DOI - PubMed
99. 1. Leff M. J., Roatch J. F., Bunney W. E. (1970). Environmental factors preceding onset of severe depressions. Psychiatry 33, 293–311 - PubMed
100. 1. Lemke T. L., Williams D. A., Roche V. F., Zito S. W. (2010). Foye's Principles of Medicinal Chemistry. Baltimore, MD: Lippincott Williams & Wilkins
101. 1. Little R. J. A., Rubin D. B. (1989). The analysis of social science data with missing values. Sociol. Methods Res. 18, 292–32610.1177/0049124189018002004 - DOI
102. 1. Lochmiller R. L., Deerenberg C. (2000). Trade-offs in evolutionary immunology: just what is the cost of immunity? Oikos 88, 87–9810.1034/j.1600-0706.2000.880110.x - DOI
103. 1. Lustman P. J., Clouse R. E., Nix B. D., Freedland K. E., Rubin E. H., Mcgill J. B., Williams M. M., Gelenberg A. J., Ciechanowski P. S., Hirsch I. B. (2006). Sertraline for prevention of depression recurrence in diabetes mellitus - A randomized, double-blind, placebo-controlled trial. Arch. Gen. Psychiatry 63, 521–52910.1001/archpsyc.63.5.521 - DOI - PubMed
104. 1. Marien M., Floutard J., Ladure P. (2007). Effect of milnacipran on extracellular levels of noradrenaline, dopamine and serotonin (5-HT) in the medial prefrontal cortex of freely moving rats, as measured by intracerebral microdialysis. Fundam. Clin. Pharmacol. 21, 386
105. 1. Mayorga A. J., Dalvi A., Page M. E., Zimov-Levinson S., Hen R., Lucki I. (2001). Antidepressant-like behavioral effects in 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B) receptor mutant. J. Pharmacol. Exp. Ther. 298, 1101–1107 - PubMed
106. 1. McEwen B. S. (1998). Protective and damaging effects of stress mediators. N. Engl. J. Med. 338, 171–17910.1056/NEJM199801153380307 - DOI - PubMed
107. 1. McEwen B. S. (2007). Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol. Rev. 87, 873–90410.1152/physrev.00041.2006 - DOI - PubMed
108. 1. McGrath P. J., Stewart J. W., Quitkin F. M., Ying C., Alpert J. E., Nierenberg A. A., Fava M., Cheng J., Petkova E. (2006). Predictors of relapse in a prospective study of fluoxetine treatment of major depression. Am. J. Psychiatry 163, 1542–154810.1176/appi.ajp.163.9.1542 - DOI - PubMed
109. 1. Michelson D., Fava M., Amsterdam J., Apter J., Londborg P., Tamura R., Tepner R. G. (2000). Interruption of selective serotonin reuptake inhibitor treatment: double-blind, placebo-controlled trial. Br. J. Psychiatry 176, 363–36810.1192/bjp.176.4.363 - DOI - PubMed
110. 1. Mindham R. H. S., Howland C., Shepherd M. (1973). Evaluation of continuation therapy with tricyclic antidepressants in depressive illness. Psychol. Med. 3, 5–1710.1017/S0033291700046304 - DOI - PubMed
111. 1. Moffitt T. E., Caspi A., Taylor A., Kokaua J., Milne B. J., Polanczyk G., Poulton R. (2009). How common are mental disorders? Evidence that lifetime prevalence rates are doubled by prospective versus retrospective ascertainment. Psychol. Med. 40, 899–90910.1017/S0033291709991036 - DOI - PMC - PubMed
112. 1. Montgomery S. A., Asberg M. (1979). A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134, 382–38910.1192/bjp.134.4.382 - DOI - PubMed
113. 1. Montgomery S. A., Dufour H., Brion S., Gailledreau J., Laqueille X., Ferrey G., Moron P., Parant-Lucena N., Singer L., Danion J. M., Beuzen J. M., Pierredoin M. A. (1988). The prophylactic efficacy of fluoxetine in unipolar depression. Br. J. Psychiatry 153 (Suppl. 3), 69–76 - PubMed
114. 1. Montgomery S. A., Dunbar G. (1993). Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int. Clin. Psychopharmacol. 8, 189–19510.1097/00004850-199300830-00009 - DOI - PubMed
115. 1. Montgomery S. A., Entsuah R., Hackett D., Kunz N. R., Rudolph R. L. (2004). Venlafaxine versus placebo in the preventive treatment of recurrent major depression. J. Clin. Psychiatry 65, 328–33610.4088/JCP.v65n1123b - DOI - PubMed
116. 1. Montgomery S. A., Rasmussen J. G. C., Lyby K., Connor P., Tanghoj P. (1992). Dose-response relationship of citalopram 20 mg, citalopram 40 mg and placebo in the treatment of moderate and severe depression. Int. Clin. Psychopharmacol. 6, 65–7010.1097/00004850-199206005-00008 - DOI - PubMed
117. 1. Montgomery S. A., Rasmussen J. G. C., Tanghoj P. (1993). A 24 week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. Int. Clin. Psychopharmacol. 8, 181–18810.1097/00004850-199300820-00010 - DOI - PubMed
118. 1. Montgomery S. A., Reimitz P. E., Zivkov M. (1998). Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study. Int. Clin. Psychopharmacol. 13, 63–7310.1097/00004850-199809005-00010 - DOI - PubMed
119. 1. Nesse R. M. (2000). Is depression an adaptation? Arch. Gen. Psychiatry 57, 14–2010.1001/archpsyc.57.1.14 - DOI - PubMed
120. 1. Nesse R. M. (2004). Natural selection and the elusiveness of happiness. Philos. Trans. R. Soc. Lond. BBiol. Sci. 359, 1333–134710.1098/rstb.2004.1511 - DOI - PMC - PubMed
121. 1. Nesse R. M., Ellsworth P. C. (2009). Evolution, emotions, and emotional disorders. Am. Psychologist 64, 129–13910.1037/a0013503 - DOI - PubMed
122. 1. Nestler E. J., Aghajanian G. K. (1997). Molecular and cellular basis of addiction. Science 278, 58–6310.1126/science.278.5335.58 - DOI - PubMed
123. 1. Nestler E. J., Gould E., Manji H., Bucan M., Duman R. S., Gershenfeld H. K., Hen R., Koester S., Lederhendler I., Meaney M., Robbins T., Winsky L., Zalcman S. (2002). Preclinical models: status of basic research in depression. Biol. Psychiatry 52, 503–52810.1016/S0006-3223(02)01405-1 - DOI - PubMed
124. 1. Parent M. B., Habib M. K., Baker G. B. (2000). Time-dependent changes in brain monoamine oxidase activity and in brain levels of monoamines and amino acids following acute administration of the antidepressant/antipanic drug phenelzine. Biochem. Pharmacol. 59, 1253–126310.1016/S0006-2952(00)00244-6 - DOI - PubMed
125. 1. Perahia D. G., Gilaberte I., Wang F. J., Wiltse C. G., Huckins S. A., Clemens J. W., Montgomery S. A., Montejo A. L., Detke M. J. (2006). Duloxetine in the prevention of relapse of major depressive disorder – Double-blind placebo-controlled study. Br. J. Psychiatry 188, 346–35310.1192/bjp.188.4.346 - DOI - PubMed
126. 1. Perahia D. G. S., Maina G., Thase M. E., Spann M. E., Wang F. J., Walker D. J., Detke M. J. (2009). Duloxetine in the prevention of depressive recurrences: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 70, 706–71610.4088/JCP.08m04756 - DOI - PubMed
127. 1. Petrakis I. L., Leslie D., Rosenheck R. (2003). The use of antidepressants in alcohol-dependent veterans. J. Clin. Psychiatry 64, 865–87010.4088/JCP.v64n0802 - DOI - PubMed
128. 1. Posternak M. A., Solomon D. A., Leon A. C., Mueller T. I., Shea M. T., Endicott J., Keller M. B. (2006). The naturalistic course of unipolar major depression in the absence of somatic therapy. J. Nervous Ment. Dis. 194, 324–32910.1097/01.nmd.0000217820.33841.53 - DOI - PubMed
129. 1. Price J. (2009). Darwinian dynamics of depression. Aust. N. Z. J. Psychiatry 43, 1029–103710.1080/00048670903002008 - DOI - PubMed
130. 1. Price J., Sloman L., Gardner R., Gilbert P., Rohde P. (1994). The social competition hypothesis of depression. Br. J. Psychiatry 164, 309–31510.1192/bjp.164.3.309 - DOI - PubMed
131. 1. Raghunathan T. E., Solenberger P. W., Van Hoewyk J. (2002). IVEware: Imputation and Variance Estimation Software User Guide [Computer software]. Ann Arbor, MI: The Regents of the University of Michigan
132. 1. Reimherr F. W., Amsterdam J. D., Quitkin F. M., Rosenbaum J. F., Fava M., Zajecka J., Beasley C. M., Jr., Michelson D., Roback P., Sundell K. (1998). Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. Am. J. Psychiatry 155, 1247–1253 - PubMed
133. 1. Renard C. E., Dailly E., Nic Dhonnchadha B. A., Hascoet M., Bourin M. (2004). Is dopamine a limiting factor of the antidepressant-like effect in the mouse forced swimming test? Prog. Neuropsychopharmacol. Biol. Psychiatry 28, 1255–125910.1016/j.pnpbp.2004.06.010 - DOI - PubMed
134. 1. Reynolds C. F., Frank E., Perel J. M., Imber S. D., Cornes C., Miller M. D., Mazumdar S., Houck P. R., Dew M. A., Stack J. A., Pollock B. G., Kupfer D. J. (1999). Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression – A randomized controlled trial in patients older than 59 years. JAMA 281, 39–4510.1001/jama.281.11.1034 - DOI - PubMed
135. 1. Rickels K., Montgomery S. A., Tourian K. A., Guelfi J. D., Pitrosky B., Padmanabhan S. K., Germain J. M., Leurent C., Brisard C. (2010). Desvenlafaxine for the prevention of relapse in major depressive disorder: results of a randomized trial. J. Clin. Psychopharmacol. 30, 18–2410.1097/JCP.0b013e3181c94c4d - DOI - PubMed
136. 1. Robert P., Montgomery S. A. (1995). Citalopram in doses of 20-60 mg Is effective in depression relapse prevention: a placebo-controlled 6-month study. Int. Clin. Psychopharmacol. 10, 29–3510.1097/00004850-199503002-00006 - DOI - PubMed
137. 1. Robinson D. S., Lerfald S. C., Bennett B., Laux D., Devereaux E., Kayser A., Corcella J., Albright D. (1991). Continuation and maintenance treatment of major depression with the monoamine oxidase inhibitor Phenelzine: a double-blind placebo controlled discontinuation study. Psychopharmacol. Bull. 27, 31–39 - PubMed
138. 1. Romanovsky A. A. (2007). Thermoregulation: some concepts have changed. Functional architecture of the thermoregulatory system. Am. J. Physiol. Regul. Integr. Comp. Physiol. 292, R37–R4610.1152/ajpregu.00668.2006 - DOI - PubMed
139. 1. Romanovsky A. A., Almeida M. C., Aronoff D. M., Ivanov A. I., Konsman J. P., Steiner A. A., Turek V. F. (2005). Fever and hypothermia in systemic inflammation: recent discoveries and revisions. Front. Biosci. 10, 2193–221610.2741/1690 - DOI - PubMed
140. 1. Rouillon F., Berdeaux G., Bisserbe J. C., Warner B., Mesbah M., Smadja C., Chwalow J. (2000). Prevention of recurrent depressive episodes with milnacipran: consequences on quality of life. J. Affect. Disord. 58, 171–18010.1016/S0165-0327(99)00109-3 - DOI - PubMed
141. 1. Rush A. J., Trivedi M. H., Wisniewski S. R., Nierenberg A. A., Stewart J. W., Warden D., Niederehe G., Thase M. E., Lavori P. W., Lebowitz B. D., McGrath P. J., Rosenbaum J. F., Sackeim H. A., Kupfer D. J., Luther J., Fava M. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry 163, 1905–191710.1176/appi.ajp.163.11.1905 - DOI - PubMed
142. 1. Sadock B. J., Sadock V. A. (2005). Kaplan & Sadock's Comprehensive Textbook of Psychiatry, 8th Edn. Philadelphia, PA: Lippincott Williams & Wilkins
143. 1. Sapolsky R. M. (1996). Why stress is bad for your brain. Science 273, 749–75010.1126/science.273.5276.749 - DOI - PubMed
144. 1. Sapolsky R. M. (2000). The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death. Biol. Psychiatry 48, 755–76510.1016/S0006-3223(00)00971-9 - DOI - PubMed
145. 1. Sapolsky R. M. (2001). Depression, antidepressants, and the shrinking hippocampus. Proc. Natl. Acad. Sci. U.S.A. 98, 12320–1232210.1073/pnas.231475998 - DOI - PMC - PubMed
146. 1. Sapolsky R. M. (2004). Why Zebras Don't Get Ulcers, 3rd Edn. New York, NY: Henry Holt and Company
147. 1. Savitz J. B., Drevets W. C. (2009). Imaging phenotypes of major depressive disorder: genetic correlates. Neuroscience 164, 300–33010.1016/j.neuroscience.2009.03.082 - DOI - PMC - PubMed
148. 1. Schmidt M. E., Fava M., Robinson J. M., Judge R. (2000). The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder. J. Clin. Psychiatry 61, 851–85710.4088/JCP.v61n1107 - DOI - PubMed
149. 1. Schulman C. I., Namias N., Doherty J., Manning R. J., Li P., Elhaddad A., Lasko D., Amortegui J., Dy C. J., Dlugasch L., Baracco G., Cohn S. M. (2005). The effect of antipyretic therapy upon outcomes in critically ill patients: a randomized, prospective study. Surg. Infect. (Larchmt) 6, 369–37510.1089/sur.2005.6.369 - DOI - PubMed
150. 1. Seo D. O., Shin C. Y., Lee C. J., Dailey J. W., Reith M. E. A., Jobe P. C., Ko K. H. (1999). Effect of alterations in extracellular norepinephrine on adrenoceptors: a microdialysis study in freely moving rats. Eur. J. Pharmacol. 365, 39–4610.1016/S0014-2999(98)00856-5 - DOI - PubMed
151. 1. Simon J. S., Aguiar L. M., Kunz N. R., Lei D. (2004). Extended-release venlafaxine in relapse prevention for patients with major depressive disorder. J. Psychiatr. Res. 38, 249–25710.1016/j.jpsychires.2004.04.001 - DOI - PubMed
152. 1. Spitzer R. L. (2007). Foreword. New York, NY: Oxford University Press
153. 1. Spitzer R. L., Wakefield J. C. (1999). DSM-IV diagnostic criterion for clinical significance: does it help solve the false positives problem? Am. J. Psychiatry 156, 1856–1864 - PubMed
154. 1. Stahl S. (2008). Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 3rd Edn. Cambridge: Cambridge University Press
155. 1. Stein M. K., Rickels K., Weise C. C. (1980). Maintenance therapy with amitriptyline: controlled trial. Am. J. Psychiatry 137, 370–371 - PubMed
156. 1. Stewart J. W., Tricamo E., McGrath P. J., Quitkin F. M. (1997). Prophylactic efficacy of phenelzine and imipramine in chronic atypical depression: likelihood of recurrence on discontinuation after 6 months’ remission. Am. J. Psychiatry 154, 31–36 - PubMed
157. 1. Takahashi H., Takada Y., Nagai N., Urano T., Takada A. (2000). Serotonergic neurons projecting to hippocampus activate locomotion. Brain Res. 869, 194–20210.1016/S0006-8993(00)02385-4 - DOI - PubMed
158. 1. Tanda G., Carboni E., Frau R., Dichiara G. (1994). Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential. Psychopharmacology (Berl.) 115, 285–28810.1007/BF02244785 - DOI - PubMed
159. 1. Terra J. L., Montgomery S. A. (1998). Fluvoxamine prevents recurrence of depression: results of a long-term, double-blind, placebo-controlled study. Int. Clin. Psychopharmacol. 13, 55–6210.1097/00004850-199809005-00011 - DOI - PubMed
160. 1. Tomlinson K. L., Tate S. R., Anderson K. G., McCarthy D. M., Brown S. A. (2006). An examination of self-medication and rebound effects: psychiatric symptomatology before and after alcohol or drug relapse. Addict. Behav. 31, 461–47410.1016/j.addbeh.2005.05.028 - DOI - PubMed
161. 1. Turner E. H., Matthews A. M., Linardatos E., Tell R. A., Rosenthal R. (2008). Selective publication of antidepressant trials and its influence on apparent efficacy. N. Engl. J. Med. 358, 252–26010.1056/NEJMsa065779 - DOI - PubMed
162. 1. Uylings H. B. M., Groenewegen H. J., Kolb B. (2003). Do rats have a prefrontal cortex? Behav. Brain Res. 146, 3–1710.1016/j.bbr.2003.09.028 - DOI - PubMed
163. 1. Uylings H. B. M., Vaneden C. G. (1990). Qualitative and quantitative comparison of the prefrontal cortex in rat and in primates, including humans. Prog. Brain Res. 85, 31–62 - PubMed
164. 1. Valenstein E. S. (1998). Blaming the Brain: The Truth About Drugs and Mental Health. New York, NY: The Free Press
165. 1. Valentini V., Cacciapaglia F., Frau R., Di Chiara G. (2005). Selective serotonin reuptake blockade increases extracellular dopamine in noradrenaline-rich isocortical but not prefrontal areas: dependence on serotonin-1A receptors and independence from noradrenergic innervation. J. Neurochem. 93, 371–38210.1111/j.1471-4159.2005.03030.x - DOI - PubMed
166. 1. Valentini V., Frau R., Di Chiara G. (2004). Noradrenaline transporter blockers raise extracellular dopamine in medial prefrontal but not parietal and occipital cortex: differences with mianserin and clozapine. J. Neurochem. 88, 917–92710.1046/j.1471-4159.2003.02238.x - DOI - PubMed
167. 1. van Praag H., de Haan S. (1980). Depression vulnerability and 5-hydroxytryptophan prophylaxis. Psychiatry Res 3, 75–8310.1016/0165-1781(80)90049-9 - DOI - PubMed
168. 1. Viguera A. C., Baldessarini R. J., Friedberg J. (1998). Discontinuing antidepressant treatment in major depression. Harv. Rev. Psychiatry 5, 293–30610.3109/10673229809003578 - DOI - PubMed
169. 1. Wakefield J. C. (1992). The concept of mental disorder: on the boundary between biological facts and social values. Am. Psychologist 47, 373–38810.1037/0003-066X.47.3.373 - DOI - PubMed
170. 1. Wakefield J. C., Schmitz M. F., Baer J. C. (2010). Does the DSM-IV clinical significance criterion for major depression reduce false positives? Evidence from the National Comorbidity Survey replication. Am. J. Psychiatry 167, 298–30410.1176/appi.ajp.2009.09040553 - DOI - PubMed
171. 1. Wakefield J. C., Schmitz M. F., First M. B., Horwitz A. V. (2007). Extending the bereavement exclusion for major depression to other losses - Evidence from the National Comorbidity Survey. Arch. Gen. Psychiatry 64, 433–44010.1001/archpsyc.64.4.433 - DOI - PubMed
172. 1. Watson P. J., Andrews P. W. (2002). Toward a revised evolutionary adaptationist analysis of depression: the social navigation hypothesis. J. Affect. Disord. 72, 1–1410.1016/S0165-0327(02)00366-X - DOI - PubMed
173. 1. Weikop P., Kehr J., Scheel-Kruger J. (2007). Reciprocal effects of combined administration of serotonin, noradrenaline and dopamine reuptake inhibitors on serotonin and dopamine levels in the rat prefrontal cortex: the role of 5-HT1A receptors. J. Psychopharmacol. 21, 795–80410.1177/0269881107077347 - DOI - PubMed
174. 1. Wells J. E., Horwood L. J. (2004). How accurate is recall of key symptoms of depression? A comparison of recall and longitudinal reports. Psychol. Med. 34, 1001–101110.1017/S0033291703001843 - DOI - PubMed
175. 1. Wilson K. C. M., Mottram P. G., Ashworth L., Abou-Saleh M. T. (2003). Older community residents with depression: long-term treatment with sertraline – Randomised, double-blind, placebo-controlled study. Br. J. Psychiatry 182, 492–49710.1192/bjp.182.6.492 - DOI - PubMed
176. 1. Wolowczuk I., Verwaerde C., Viltart O., Delanoye A., Delacre M., Pot B., Grangette C. (2008). Feeding our immune system: impact on metabolism. Clin. Dev. Immunol. 1–1910.1155/2008/639803 - DOI - PMC - PubMed
177. 1. Woods A. H. (2009). “Evolution of homeostatic physiological systems,” in Phenotypic Plasticity of Insects, eds Whitman D., Ananthakrishnan T. N. (Plymouth: Science Publishers; ), 655–674
178. 1. Wrosch C., Miller G. E. (2009). Depressive symptoms can be useful: self-regulatory and emotional benefits of dysphoric mood in adolescence. J. Pers. Soc. Psychol. 96, 1181–119010.1037/a0015172 - DOI - PubMed
179. 1. Young A. M., Goudie A. J. (1995). “Adaptive processes regulating tolerance to behavioral effects of drugs,” in Psychopharmacology: 4th Generation of Progress, eds Bloom F. E., Kupfer D. J. (New York, NY: Raven Press; ), 733–742
180. 1. Zimmerman M., Posternak M. A., Ruggero C. J. (2007). Impact of study design on the results of continuation studies of antidepressants. J. Clin. Psychopharmacol. 27, 177–18110.1097/JCP.0b013e31803308e1 - DOI - PubMed